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were fixed to ensure adequate target coverage; all other 
priorities were automatically set by RapidPlan. Following 
plan optimization each plan was assessed against clinical 
dose constraints and if necessary, objective priorities were 
adjusted and optimization repeated until a clinically 
acceptable plan was achieved.  
Results: Acceptable plans were produced using the initial 
objectives without further planner intervention for 4 out of 
10 patients. A maximum of 2 iterations of priority 
adjustments was required to optimize plans for the remaining 
patients. Mean dose statistics for the final plans are shown in 
Table 1. The RapidPlan plans showed a significant (P<0.05) 
increase in target coverage (measure by the D99%) for all PTVs 
and a significant reduction in mean bladder and rectal doses. 
This was largely due to a reduction in OAR DVHs at low to 
moderate doses, as the maximum rectal and bladder doses 
were slightly increased. MUs were generally higher than for 
clinical plans, but the difference was not found to be 
significant.  
Table 1 Summary of average (range) dose statistics and MUs 
comparing RapidPlan with original treatment plans. 
 
 
Conclusions: With a model based on local plan data, it was 
possible to efficiently produce clinically acceptable prostate 
plans using RapidPlan. OAR doses were generally reduced and 
target coverage increased; target minimum dose priorities 
may need to be adjusted to optimize the balance between 
target coverage and OAR maximum doses. This could improve 
efficiency by reducing the proportion of patients for whom 
additional planner intervention is required. Our first clinical 
plan produced using RapidPlan has been clinically approved, 
with the patient due to start treatment in December 2014.  
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Purpose/Objective: The aim was to investigate the 
differences between Ray-Tracing and Monte Carlo dose 
calculation algorithm for treatment of non-small cell lung 
cancer (NSCLC) patients using Cyberknife (Accuray, 
Sunnyvale, US). Special attention was paid on physical and 
biological dose and tumor control probability (TCP) 
differences. 
Materials and Methods: Twenty six patients (with a total of 
30 lesions) in early stage NSCLC were administered 
stereotactic ablative radiotherapy (SABR) in our institution 
using Cyberknife. For all patients clinical target volume (CTV) 
to planning target volume (PTV) margin varied between 2 and 
5 mm and was tracking-method dependant. Risk-adapted 
dose prescription scheme was used for several patients who 
were not suitable for the intended 3 times 20 Gy. 
Retrospective dose calculation with Monte Carlo (MC) was 
performed on plans previously calculated with the Ray-
Tracing (RT) algorithm. Monitor unit and beam orientation 
were preserved. Biologically relevant dose differences were 
analyzed using CTV's mean dose and generalized equivalent 
uniform dose (gEUD) using an a value of -10, to give higher 
importance to lower doses. Physical dose differences were 
collected combined with the corresponding biological 
equivalent dose (BED10) using the method suggested by (Ohri 
& al. IJROBP 2012). Furthermore tumor control differences 
were assessed using a TCP model established for lung SBRT 
and taking into account the size of the target. Differences 
between the two algorithm were tested using a paired t-test 
with a significance level of p<0.05. 
Results: CTV volume and spherically approximated diameter 
were on average 20.7 cc (sd = 19.6 cc) and 3 cm (sd = 1.2 
cm). Focusing on physical dose differences (RT vs. MC) of the 
CTV, average mean dose and gEUD were 62.6 (9.4) vs. 48.5 
(8.1) and 61.4 (10.3) vs. 41.1 (10.5) Gy. Physical dose 
differences (mean/gEUD) higher than 20% were found for 50 
% / 57% of the patients. Corresponding biological dose 
differences were on average 194 (50) vs. 127 (36) and 188 
(53) vs. 99 (40) Gy respectively for mean and gEUD doses. 
This lead in 85% of the cases more than 10Gy BED decrease. 
Associated TCP were on average 92 (3) % vs. 97(5) % and 
94(5) % vs. 86(11) %. Nearly half of the patient population 
(46.7%) presented gEUD-based TCP differences higher than 
10% vs. 2 patients (6.7%) for the mean dose-based TCP. All of 
the differences were statistically significant (p<0.001) in 
every aspect.  
Summary of the result are presented in Figure 1 using a 
boxplot representation. 
 
 
Figure 1. Mean dose vs. gEUD to describe a) physical dose, b) 
biological equivalent dose and c) tumor control probability 
differences between Ray-Tracing and Monte Carlo algorithm 
 
Conclusions: Dose calculation differences between RT and 
MC algorithm could lead into severe differences in physical 
and biological doses which could dramatically worsened the 
TCP. Clinical follow-up is necessary to confirm the finding. 
 
 
